{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:50:04Z","timestamp":1777654204607,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,4,28]],"date-time":"2012-04-28T00:00:00Z","timestamp":1335571200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pyoderma gangrenosum (PG) is a rare inflammatory skin disorder characterised by painful and rapidly progressing skin ulceration. PG can be extremely difficult to treat and patients often require systemic immunosuppression. Recurrent lesions of PG are common, but the relative rarity of this condition means that there is a lack of published evidence regarding its treatment. A systematic review published in 2005 found no randomised controlled trials (RCTs) relating to the treatment of PG. Since this time, one small RCT has been published comparing infliximab to placebo, but none of the commonly used systemic treatments for PG have been formally assessed. The UK Dermatology Clinical Trials Network\u2019s STOP GAP Trial has been designed to address this lack of trial evidence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The objective is to assess whether oral ciclosporin is more effective than oral prednisolone for the treatment of PG. The trial design is a two-arm, observer-blind, parallel-group, randomised controlled trial comparing ciclosporin (4\u2009mg\/kg\/day) to prednisolone (0.75\u2009mg\/kg\/day). A total of 140 participants are to be recruited over a period of 4\u2009years, from up to 50 hospitals in the UK and Eire. Primary outcome of velocity of healing at 6\u2009weeks is assessed blinded to treatment allocation (using digital images of the ulcers). Secondary outcomes include: (i) time to healing; (ii) global assessment of improvement; (iii) PG inflammation assessment scale score; (iv) self-reported pain; (v) health-related quality of life; (vi) time to recurrence; (vii) treatment failures; (viii) adverse reactions to study medications; and (ix) cost effectiveness\/utility. Patients with a clinical diagnosis of PG (excluding granulomatous PG); measurable ulceration (that is, not pustular PG); and patients aged over 18\u2009years old who are able to give informed consent are included in the trial. Randomisation is by computer generated code using permuted blocks of randomly varying size, stratified by lesion size, and presence or absence of underlying systemic disease (for example, rheumatoid arthritis).<\/jats:p>\n            <jats:p>Patients who require topical therapy are asked to enter a parallel observational study (case series). If topical therapy fails and systemic therapy is required, participants are then considered for inclusion in the randomised trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Current controlled trials: ISRCTN35898459. Eudract No.2008-008291-14.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1745-6215-13-51","type":"journal-article","created":{"date-parts":[[2012,4,28]],"date-time":"2012-04-28T14:16:18Z","timestamp":1335622578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["UK Dermatology Clinical Trials Network\u2019s STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"13","author":[{"given":"Fiona F","family":"Craig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim S","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor J","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hywel C","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Norrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D","family":"Ormerod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,28]]},"reference":[{"key":"1021_CR1","first-page":"1","volume":"1","author":"F Craig","year":"2011","unstructured":"Craig F, Ormerod A: Pyoderma gangrenosum: pathogenesis, diagnosis, classification and treatment. J Clin Dermatol. 2011, 1: 1-9.","journal-title":"J Clin Dermatol"},{"key":"1021_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0190-9622(96)90428-4","volume":"34","author":"FC Powell","year":"1996","unstructured":"Powell FC, Daniel Su WP, Perry HO: Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996, 34: 395-409. 10.1016\/S0190-9622(96)90428-4.","journal-title":"J Am Acad Dermatol"},{"key":"1021_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00005792-200001000-00004","volume":"79","author":"ML Bennett","year":"2000","unstructured":"Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, White WL, Callen J: Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000, 79: 37-46. 10.1097\/00005792-200001000-00004.","journal-title":"Medicine (Baltimore)"},{"key":"1021_CR4","first-page":"173","volume":"55","author":"FC Powell","year":"1985","unstructured":"Powell FC, Schroeter AL, Su WP, Perry HO: Pyoderma gangrenosum: a review of 86 patients. Q J Med. 1985, 55: 173-186.","journal-title":"Q J Med"},{"key":"1021_CR5","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1046\/j.1365-2133.1997.20022083.x","volume":"167","author":"P von den Driesch","year":"1997","unstructured":"von den Driesch P: Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997, 167: 1000-1005.","journal-title":"Br J Dermatol"},{"key":"1021_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jaad.2004.10.006","volume":"53","author":"J Reichrath","year":"2005","unstructured":"Reichrath J, Bens G, Bonowitz A: Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005, 53: 273-283. 10.1016\/j.jaad.2004.10.006.","journal-title":"J Am Acad Dermatol"},{"key":"1021_CR7","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.2310\/7750.2009.00002","volume":"13","author":"V Prajapati","year":"2009","unstructured":"Prajapati V, Man J, Brassard A: Pyoderma gangrenosum: common pitfalls in management and a stepwise, evidence-based, therapeutic approach. J Cutan Med Surg. 2009, 13: S2-S11.","journal-title":"J Cutan Med Surg"},{"key":"1021_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS: Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006, 55: 505-509. 10.1136\/gut.2005.074815.","journal-title":"Gut"},{"key":"1021_CR9","unstructured":"STOP GAP Trial: STOP GAP Trial website. [http:\/\/www.stopgaptrial.co.uk]"},{"key":"1021_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/095466301750163518","volume":"12","author":"CC Lyon","year":"2001","unstructured":"Lyon CC, Stapleton M, Smith AJ, Mendelsohn S, Beck MH, Griffiths CE: Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatolog Treat. 2001, 12: 13-17. 10.1080\/095466301750163518.","journal-title":"J Dermatolog Treat"},{"key":"1021_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s10227-004-0105-9","volume":"8","author":"H Nybaek","year":"2004","unstructured":"Nybaek H, Olsen AG, Karlsmark T, Jemec GB: Topical therapy for peristomal pyoderma gangrenosum. J Cutan Med Surg: Inc Med Surg Dermatol. 2004, 8: 220-223.","journal-title":"J Cutan Med Surg: Inc Med Surg Dermatol"},{"key":"1021_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0168-8227(00)00145-5","volume":"49","author":"RP Wunderlich","year":"2000","unstructured":"Wunderlich RP, Peters EJ, Armstrong DG, Lavery LA: Reliability of digital videomatery and acetate tracing in measuring the surface area of cutaneous wounds. Diabetes Res Clin Pract. 2000, 49: 87-92. 10.1016\/S0168-8227(00)00145-5.","journal-title":"Diabetes Res Clin Pract"},{"key":"1021_CR13","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1046\/j.1365-2133.2000.03478.x","volume":"142","author":"J Kantor","year":"2000","unstructured":"Kantor J, Margolis DJ: A multi-centre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24\u2009weeks. Br J Dermatol. 2000, 142: 960-964. 10.1046\/j.1365-2133.2000.03478.x.","journal-title":"Br J Dermatol"},{"key":"1021_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1468-3083.2008.02680.x","volume":"22","author":"CE Foss","year":"2008","unstructured":"Foss CE, Clark AR, Inabinet R, Camacho F, Jorizzo JL: An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum. J Euro Acad Dermatol. 2008, 22: 943-949. 10.1111\/j.1468-3083.2008.02680.x.","journal-title":"J Euro Acad Dermatol"},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994, 19: 210-216. 10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"key":"1021_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brookes","year":"1996","unstructured":"Brookes R: EuroQol - the current state of play. Health Policy. 1996, 37: 53-72. 10.1016\/0168-8510(96)00822-6.","journal-title":"Health Policy"},{"key":"1021_CR17","unstructured":"UK Dermatology Clinical Trials Network: UK Dermatology Clinical Trials Network's website. [http:\/\/www.ukdctn.org]"},{"key":"1021_CR18","unstructured":"NIHR Clinical Research Network: NIHR Clinical Research Network website. [http:\/\/www.crncc.nihr.ac.uk]"},{"key":"1021_CR19","unstructured":"Nottingham Clinical Trials Unit: Nottingham Clinical Trials Unit website. [http:\/\/ctu.nottingham.ac.uk]"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-13-51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1745-6215-13-51\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-13-51","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-13-51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:30:14Z","timestamp":1630524614000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-13-51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,28]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-13-51","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,28]]},"assertion":[{"value":"15 December 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"51"}}